GoodRx Holdings GDRX 深 滬
等待開盤 12-23 09:30:00 美东时间
2.73
-0.040
-1.44%
華盛通- 最 高2.82
- 今 開2.76
- 成交量 117.10万股
- 最 低 2.73
- 昨 收 2.77
- 總市值 9.25亿
- 52周最高 5.8099
- 市盈率 靜 65.31
- 換手率 0.35%
- 52周最低 2.61
- 委 比 -47.86%
- 總股本 3.39亿
- 歷史最高 64.219
- 量 比 0.49
- 振 幅 3.25%
- 歷史最低 2.61
- 每 手 1
- 風險率 0.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $4
Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and lowers the price target from $5 to $4.
12-19 01:56
GoodRx Approves Retention Bonuses for CEO and CFO
The latest update is out from GoodRx Holdings ( ($GDRX) ). On December 9, 2025,...
12-13 05:47
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Barclays Initiates Coverage On GoodRx Holdings with Underweight Rating, Announces Price Target of $3
Barclays analyst Glen Santangelo initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Underweight rating and announces Price Target of $3.
12-09 23:47
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbus...
11-22 02:58
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
11-18 02:01
GoodRx launches $39 per month weight loss telemedicine subscription
GoodRx (GDRX) announced two major initiatives on Monday to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that con...
11-17 21:50
Novo Nordisk cuts Wegovy, Ozempic direct-to-user prices to match Eli Lilly’s Zepbound
Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more aggressive push to regain U.S. market share. “Wegovy (semaglutide) injection 0.25 m...
11-17 21:25
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
